|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2022
|
|
gptkbp:ATCCode
|
J06BD10
|
|
gptkbp:brand
|
Beyfortus
|
|
gptkbp:CASNumber
|
2227365-35-6
|
|
gptkbp:chemicalClass
|
IgG1 kappa monoclonal antibody
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:Sanofi
|
|
gptkbp:halfLife
|
approximately 70 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nirsevimab
|
|
gptkbp:indication
|
prevention of RSV lower respiratory tract disease in infants
prevention of RSV in neonates and infants born during or entering their first RSV season
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to RSV F protein
|
|
gptkbp:pregnancyCategory
|
not assigned
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:target
|
RSV fusion (F) protein
|
|
gptkbp:UNII
|
1Q1V9F1Q1F
|
|
gptkbp:usedFor
|
prevention of respiratory syncytial virus (RSV) infection
|
|
gptkbp:bfsParent
|
gptkb:respiratory_syncytial_virus
|
|
gptkbp:bfsLayer
|
6
|